ArticleBone2025
AGEs (Advanced Glycation End-products) in bone come of age.
Article in Bone, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Bone Aging and Glycative Stress: Convergent and Divergent Mechanisms Driving Skeletal Deterioration.Cells · 2026Review
- Trabecular bone score differs among prediabetes phenotypes: the potential mediating role of visceral adiposity.The Korean journal of internal medicine · 2026Article
- Effect of Canagliflozin Pretreatment on the Efficacy of Insulin Therapy to Rescue Type 1 Diabetes-Related Bone Fragility in Male Mice.Calcified tissue international · 2026Article
- In Vivo Models of Diabetes: Unravelling Molecular Pathways in Metabolic and Skeletal Complications.Biomedicines · 2026Review
- Association of the metabolic score for insulin resistance with bone mineral density and trabecular bone score in cancer patients: a cross-sectional study.Frontiers in endocrinology · 2026Article
- Mechanistic Insight into Phenolic Compounds in Mitigating Diabetic Complications Induced by Advanced Glycation End Products.Current issues in molecular biology · 2025Review
- Charcot foot disease: A new approach.Drugs & aging · 2025Review
- The Association Between Two Different Non-invasive Advanced Glycation End Products and Osteoporosis in the Non-diabetic Population: A Cross-Sectional Study.Calcified tissue international · 2025Article
- Pathological and Inflammatory Consequences of Aging.Biomolecules · 2025Review
- Systemic immune-inflammation index to albumin (SII/ALB) ratio as a novel dual-dimensional powerful predictor for hip fractures in elderly females with diabetes: a postmenopausal longitudinal cohort study.BMC endocrine disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Advanced Glycation End-products (AGEs) are seen in long-lived proteins and were not expected to accumulate in the bone that turnovers and renews itself. Here, we provide a commentary on the contrary, highlighting the Special Issue of AGEs in Bone. An outcome of hyperglycemia and increased oxidative stress, AGEs form and accumulate by altering the bone resorption and formation processes. Accumulation of various AGEs species in bone increases bone fragility through the stiffening of the collagen network and, potentially, through the changes in collagen-mineral interactions. Evidence from both preclinical and clinical studies is leading to new translational approaches wherein measurement, inhibition, or removal of AGEs show the potential to diagnose, manage, and treat bone fragility associated with multiple conditions and diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.